Evidence map›Paper›PMID 39504377›Full record

ArticleScience advances2024

Dormancy-inducing 3D engineered matrix uncovers mechanosensitive and drug-protective FHL2-p21 signaling axis.

Sadra Bakhshandeh, Unai Heras, Hubert M Taïeb, Adithi R Varadarajan, Susanna M Lissek, Sarah M Hücker, Xin Lu, Daniela S Garske, Sarah A E Young, Andrea Abaurrea and 10 more

Abstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Mechanisms of breast cancer dormancy in bone metastasis.Clinical & experimental metastasis · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sadra BakhshandehDepartment of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.
Unai HerasGroup of Bioengineering in Regeneration and Cancer, Biogipuzkoa Health Research Institute, San Sebastian, Spain.ORCID 0000-0001-5315-0502
Hubert M TaïebDepartment of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.ORCID 0000-0002-7530-8988
Adithi R VaradarajanDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.ORCID 0000-0002-9581-8598
Susanna M LissekExperimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.ORCID 0000-0003-2095-8024
Sarah M HückerDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.ORCID 0000-0002-6167-0265
Xin LuDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.
Daniela S GarskeDepartment of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.ORCID 0000-0002-9784-0756
Sarah A E YoungDepartment of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.ORCID 0000-0003-3862-3863
Andrea AbaurreaGroup of Breast Cancer, Biogipuzkoa Health Research Institute, San Sebastian, Spain.ORCID 0000-0001-9493-0548
Maria M CaffarelGroup of Breast Cancer, Biogipuzkoa Health Research Institute, San Sebastian, Spain.ORCID 0000-0002-7442-6827
Ana RiestraDepartment of Pharmacy, Fundación Onkologikoa Fundazioa, San Sebastian, Spain.ORCID 0000-0002-8986-0247
Paloma BragadoDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.ORCID 0000-0002-7642-1245
Jörg ContzenDepartment of Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-8964-6208
Manfred GossenInstitute of Active Polymers, Helmholtz-Zentrum Hereon, Teltow, Germany.ORCID 0000-0002-1761-4063
Stefan KirschDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.
Jens WarfsmannDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.ORCID 0000-0001-5041-2925
Kamran HonarnejadDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.
Christoph A KleinDivision of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.ORCID 0000-0001-7128-1725
Amaia CipitriaDepartment of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.ORCID 0000-0002-9918-1512

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solid cancers frequently relapse with distant metastasis, despite local and systemic treatment. Cellular dormancy has been identified as an important mechanism underlying drug resistance enabling late relapse. Therefore, relapse from invisible, minimal residual cancer of seemingly disease-free patients call for in vitro models of dormant cells suited for drug discovery. Here, we explore dormancy-inducing 3D engineered matrices, which generate mechanical confinement and induce growth arrest and survival against chemotherapy in cancer cells. We characterized the dormant phenotype of solitary cells by P-ERK

Indexed as

Cyclin-Dependent Kinase Inhibitor p21LIM-Homeodomain ProteinsMuscle ProteinsSignal TransductionTranscription FactorsAnimalsAntineoplastic AgentsCell Line, TumorDrug Resistance, NeoplasmHumansMiceNeoplasmsAntineoplastic AgentsCyclin-Dependent Kinase Inhibitor p21FHL2 protein, humanLIM-Homeodomain ProteinsMuscle ProteinsTranscription Factors

Identifiers

PMID39504377
PMCPMC11540038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.